Oral Nalbuphine in Idiopathic Pulmonary Fibrosis–Associated Cough

Oral Nalbuphine in Idiopathic Pulmonary Fibrosis-Associated CoughThis study evaluated whether oral nalbuphine extended release (ER) reduces cough and improves patient-reported outcomes in patients with idiopathic pulmonary fibrosis (IPF) and chronic cough. Why Does This Clinical Trial Matter?IPF is a progressive lung disease with high rates of mortality and significant impairment in quality of life.Up to 80% of patients with IPF experience chronic cough and current treatments do not effectively address this symptom.New options are needed.